
Spondyloarthropathies encompass axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axSpA, as well as psoriatic arthritis and enteropathic arthritis, sharing HLA-B27 association and overlapping clinical features. TNF inhibitors, IL-17 inhibitors, and JAK inhibitors have transformed management; treat-to-target strategies aiming for inactive disease are now guideline-recommended. MRI-guided early diagnosis before structural damage accumulates is a growing clinical priority.
